Progress of chimeric antigen receptor T cell therapy for mantle cell lymphoma

VernacularTitle:套细胞淋巴瘤的嵌合抗原受体T细胞治疗进展
Author: Sijia YAN ¹ ; Yi XIAO
Author Information

1. 华中科技大学同济医学院附属同济医院血液内科，武汉　430030
Keywords: Lymphoma, mantle-cell; Receptors, chimeric antigen; Receptors, antigen, T-cell; Molecular targeted therapy
From: Journal of Leukemia & Lymphoma 2024;33(12):758-761
CountryChina
Language:Chinese
Abstract: Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma. At present, combination chemotherapy is the first choice of MCL treatment, and sequential hematopoietic stem cell transplantation after chemotherapy is the preferred treatment for some young patients. Targeted therapy is the first choice for relapsed/refractory MCL, but relapse is still inevitable. Chimeric antigen receptor T (CAR-T) cell therapy has become one of the important methods in the treatment of relapsed/refractory MCL.